Free
Education  |   May 2003
Spinal Adrenergic and Cholinergic Receptor Interactions Activated by Clonidine in Postincisional Pain
Author Affiliations & Notes
  • Frédéric Duflo, M.D.
    *†
  • Dawn Conklin, B.S.
  • Xinhui Li, Ph.D.
    §
  • James C. Eisenach, M.D.
  • *Visiting Research Fellow, §Assistant Professor, ‡Laboratory Technician, ∥F.M. James III Professor of Anesthesiology, Department of Anesthesiology, Wake Forest University School of Medicine. †Department of Anesthesiology and Intensive Care Unit, Hôpital de l'Hôtel-Dieu, Lyon, France.
  • From the Department of Anesthesiology and Center for the Study of Pharmacologic Plasticity in the Presence of Pain, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Article Information
Education
Education   |   May 2003
Spinal Adrenergic and Cholinergic Receptor Interactions Activated by Clonidine in Postincisional Pain
Anesthesiology 5 2003, Vol.98, 1237-1242. doi:
Anesthesiology 5 2003, Vol.98, 1237-1242. doi:
THE α2-adrenoceptor agonists unquestionably yield antinociception in acute and in chronic pain states, both in animals and humans. 1–3 However, α2-adrenoceptor agonists, such as dexmedetomidine or clonidine, also produce sedation and cardiovascular depression after systematic or intrathecal injection, limiting their use to an adjuvant for analgesia. Among these compounds, 2-(2,6-diethylphenylamino)-2-imidazoline (ST91), a polar analog of clonidine, seems to be an attractive alternative to current agents since it produces analgesia in normal rats and in rats after nerve injury without significant hypotension, bradycardia, and sedation. 4 The favorable profile of ST91 could reflect altered distribution due to its hydrophilicity or due to receptor subtype selectivity. 5 ST91 interacts with different α2-adrenoceptors than does clonidine or dexmedetomidine, as indicated by its reversal by antagonists that do not affect these agonists 6 and by its synergy for antinociception when combined with these agonists. 7 
We have recently shown that, after peripheral nerve injury, Sprague-Dawley rats manifest remarkable changes in spinal α2-adrenoceptor agonist pharmacology for antinociception. First, we showed that the antinociceptive effect of clonidine in normal rats reflects activation of both α2A and α2non-A-adrenoceptor subtypes, whereas following spinal nerve ligation in animals, this effect is totally due to activation of α2non-A-adrenoceptor subtypes. 8 Second, in animals with peripheral injury, but not in normal animals subjected to a noxious thermal stimulus (unpublished observations, Xavier Paqueron, MD, Research Fellow, Department of Anesthesiology, Wake Forest University School of Medicine, June, 2000), clonidine loses its antinociceptive effect after destruction or antagonism of the cholinergic receptor population when the animals were subjected to a mechanical stimulus. 9 This indicates a major shift in α2-adrenoceptor mechanisms after nerve injury.
Hypersensitivity to mechanical stimuli following surgery exhibits unique pharmacology of inhibition compared with that of inflammation or nerve injury. The purpose of the current study was to evaluate the potency and efficacy of spinally administered ST91 in an experimental model for human postoperative pain when compared to clonidine. In addition, we examined which of the α2-adrenoceptor subtypes was activated by spinally injected clonidine and whether α2-adrenoceptor efficacy required interactions with spinal nicotinic and muscarinic receptors after surgery.
Materials and Methods
Surgical Preparation
The study was approved by the Animal Care and Use Committee of the Wake Forest University School of Medicine (Winston Salem, NC). Male Sprague-Dawley rats (250–300 g) obtained from Harlan (Indianapolis, IN) were used in all experiments. Animals were housed under a 12-h light–dark cycle, with food and water ad libitum  . For intrathecal drug administration, sterilized 32-gauge tubing (RecathCo, Allison Park, PA) connected to 8.5-cm Tygon® external tubing (Saint-Gobain Performance Plastics, Akron, OH) was inserted during halothane anesthesia, as previously described. 10 The catheter was passed caudally from the cisterna magnum to the level of lumbar enlargement (7.5–8.0 cm). Only animals without evidence of neurologic dysfunction after catheter insertion were studied. Correct position of the lumbar catheter was verified in a subset (n = 68) of animals after surgery. All studies were performed at least 7 days after insertion of the intrathecal catheter. Paw incision was performed as described by Brennan et al.  11 Animals were anesthetized with halothane; the plantar surface of the left hind paw was prepared with 70% ethanol; and a 1-cm longitudinal incision was made through the skin and fascia, starting 0.5 cm from the edge of the heel and extending toward the toes. The plantaris muscle was elevated and incised longitudinally. The wound was closed with two silk 5.0 sutures.
Behavioral Testing
For determining withdrawal threshold, rats were placed individually in plastic cages with a plastic mesh floor. Animals were tested after acclimation to the environment, typically 30 min after being placed in the cage. Withdrawal threshold to punctuate mechanical testing was determined using calibrated von Frey filaments (Stoelting, Wood Dale, IL), beginning with the 2.0-gauge filament. Filaments were applied vertically to an area adjacent to the wound at the heel for 4 s while the hair was bent. Brisk withdrawal or paw flinching was considered a positive response. In the absence of a response, the filament of next greater force was applied. In the presence of a response, the filament of next lower force was applied. The tactile stimulus producing a 50% likelihood of withdrawal was determined using the up–down method, as described by Chaplan et al.  12 Tests were performed in duplicate, with an approximate 3-min test-free period between withdrawal responses, and their average was used. Studies were performed on the first day after paw incision surgery.
Experimental Treatments and Drugs and Their Administration
All drugs experimental treatment was carried out 24 h after plantar incision.
The α2-adrenoceptor agonists used in this study were clonidine hydrochloride (non α2-adrenoceptor subtype selective, molecular weight of 267 g/mol, nonsubtype selective; Sigma Chemical, St. Louis, MO) and ST91 hydrochloride (α2non-A preferring, molecular weight of 254 g/mol; Boehringer Ingelheim, Ridgefield, CT). Animals received cumulative dosing at 40-min intervals of intrathecal clonidine (19, 56, 190 nmol) or at 60-min intervals of intrathecal ST91 (20, 59, 197 nmol). Timing of cumulative injections and dose range were determined in pilot experiments with each drug. Dose–response curves were constructed after conversion of withdrawal thresholds to percent maximum possible effect. Percent maximum possible effect was defined as: 100 × (postdrug response − baseline)/(prepaw incision threshold − baseline). Agonists were administered intrathecally in volumes of 10 μl, and thresholds for withdrawal were determined 40 min after clonidine administration and 60 min after ST91 injection.
The α2-adrenoceptor subtype antagonists were BRL44408, selective for the α2-A-adrenoceptor subtype, and ARC239, selective for α2-non-A-adrenoceptor subtypes (both from Tocris Cockson, Ballwin, MO). Antagonists or vehicles were injected intrathecally in a volume of 10 μl 15 min prior to agonist administration. Based on pilot experiments, we used probe doses of 94 nmol clonidine (25 μg) and 59 nmol ST91 (15 μg), and doses of 9.4 or 94 nmol BRL (n = 7–10 animals) and of 9.4 or 94 nmol ARC (n = 5–9 animals). All studies were conducted with the investigator blinded to antagonist or vehicle administered. Drugs were dissolved in normal saline or, when necessary, in 2-hydroxypropyl-β-cyclodextrin (Sigma Chemical).
Muscarinic and nicotinic cholinergic receptor antagonism was performed with intrathecal injection of atropine sulfate (44 nmol) and mecamylamine hydrochloride (491 nmol). We have previously shown that the intrathecal doses of selected antagonists inhibit corresponding cholinergic and α2-adrenoceptor ligands in rats subjected to mechanical stimuli. 8,13 
Statistical Analysis
Data are represented as mean ± SD. Dose–dependence of clonidine and ST91 was evaluated by linear regression analysis. Paw withdrawal thresholds in response to mechanical stimulation before and after paw incision were compared using a paired Student t  test. Effects of individual drugs on withdrawal thresholds were determined using a two-way analysis of variance for repeated measures followed by the Bonferroni correction for appropriate multiple comparisons. P  < 0.05 was considered significant.
Results
One hundred eighty-nine rats were included in the study. The average withdrawal threshold to punctuate mechanical stimulus before paw incision surgery was 40 ± 14 g and decreased to 4 ± 3 g within 24 h after plantar incision (P  < 0.05).
Antihypersensitivity Effect of Clonidine and ST91 in Rats after Plantar Incision
ST91 produced antihypersensitivity to von Frey filaments with similar potency but significantly greater efficacy than clonidine (fig. 1). ST91 produced transient serpentine tail movements, which were no longer present when withdrawal thresholds were evaluated. Larger doses of clonidine could not be studied due to intense behavioral sedation.
Fig. 1. Dose–response curves for the effects of intrathecally administered clonidine and ST91 on withdrawal threshold to mechanical stimulation near the paw incision site 24 h after surgery. The percent maximum possible effect (%MPE) is the percent return to presurgery withdrawal threshold. Each symbol represents the mean ± SD of 9 to 10 animals. *P  < 0.05 versus  clonidine.
Fig. 1. Dose–response curves for the effects of intrathecally administered clonidine and ST91 on withdrawal threshold to mechanical stimulation near the paw incision site 24 h after surgery. The percent maximum possible effect (%MPE) is the percent return to presurgery withdrawal threshold. Each symbol represents the mean ± SD of 9 to 10 animals. *P 
	< 0.05 versus 
	clonidine.
Fig. 1. Dose–response curves for the effects of intrathecally administered clonidine and ST91 on withdrawal threshold to mechanical stimulation near the paw incision site 24 h after surgery. The percent maximum possible effect (%MPE) is the percent return to presurgery withdrawal threshold. Each symbol represents the mean ± SD of 9 to 10 animals. *P  < 0.05 versus  clonidine.
×
α2-Adrenoceptor Antagonism of Clonidine and ST91 in Rats after Plantar Incision
Intrathecal injection of 94 nmol of clonidine increased the withdrawal threshold significantly 40 min after injection (figs. 2A and 2B). Intrathecal injection of BRL44408 and ARC239 significantly inhibited the antihypersensitivity effect of intrathecal clonidine in a dose-dependent manner (figs. 2A and 2B).
Fig. 2. Effect of intrathecal pretreatment with vehicle BRL44408 (α2A-subtype–preferring antagonist) (A  , top  ) and ARC239 (α2non-A subtype preferring antagonist) (B  , bottom  ) on withdrawal thresholds before and after paw incision and after intrathecal injection of 94 nmol clonidine. Each symbol represents the mean ± SD of 8–10 animals. *P  < 0.05 versus  preincision and control times; †P  < 0.05 versus  vehicle; $ P  < 0.05 versus  9.4 nmol dose of BRL.
Fig. 2. Effect of intrathecal pretreatment with vehicle BRL44408 (α2A-subtype–preferring antagonist) (A 
	, top 
	) and ARC239 (α2non-A subtype preferring antagonist) (B 
	, bottom 
	) on withdrawal thresholds before and after paw incision and after intrathecal injection of 94 nmol clonidine. Each symbol represents the mean ± SD of 8–10 animals. *P 
	< 0.05 versus 
	preincision and control times; †P 
	< 0.05 versus 
	vehicle; $ P 
	< 0.05 versus 
	9.4 nmol dose of BRL.
Fig. 2. Effect of intrathecal pretreatment with vehicle BRL44408 (α2A-subtype–preferring antagonist) (A  , top  ) and ARC239 (α2non-A subtype preferring antagonist) (B  , bottom  ) on withdrawal thresholds before and after paw incision and after intrathecal injection of 94 nmol clonidine. Each symbol represents the mean ± SD of 8–10 animals. *P  < 0.05 versus  preincision and control times; †P  < 0.05 versus  vehicle; $ P  < 0.05 versus  9.4 nmol dose of BRL.
×
Intrathecal injection of 59 nmol ST91 significantly increased the withdrawal threshold 60 min after injection (fig. 3A and B). Intrathecal injection of ARC239 inhibited the antihypersensitivity effect of intrathecal ST91 in a dose-dependent manner (fig. 3A). In contrast, intrathecal injection of BRL44408 failed to influence the antihypersensitivity effect of ST91 (fig. 3B). Intrathecal injection of vehicle or either antagonist alone did not alter the withdrawal threshold (control time points:figs. 2 and 3).
Fig. 3. Effect of intrathecal pretreatment with vehicle ARC239 (α2non-A-subtype–preferring antagonist) (A  , top  ) and BRL44408 (α2A-subtype–preferring antagonist) (B  , bottom  ) on withdrawal thresholds before and after paw incision and after intrathecal injection of 59 nmol ST91. Each symbol represents the mean ± SD of 5–9 animals. *P  < 0.05 versus  preincision and control times; †P  < 0.05 versus  vehicle; $ P  < 0.05 versus  0.94 nmol ARC.
Fig. 3. Effect of intrathecal pretreatment with vehicle ARC239 (α2non-A-subtype–preferring antagonist) (A 
	, top 
	) and BRL44408 (α2A-subtype–preferring antagonist) (B 
	, bottom 
	) on withdrawal thresholds before and after paw incision and after intrathecal injection of 59 nmol ST91. Each symbol represents the mean ± SD of 5–9 animals. *P 
	< 0.05 versus 
	preincision and control times; †P 
	< 0.05 versus 
	vehicle; $ P 
	< 0.05 versus 
	0.94 nmol ARC.
Fig. 3. Effect of intrathecal pretreatment with vehicle ARC239 (α2non-A-subtype–preferring antagonist) (A  , top  ) and BRL44408 (α2A-subtype–preferring antagonist) (B  , bottom  ) on withdrawal thresholds before and after paw incision and after intrathecal injection of 59 nmol ST91. Each symbol represents the mean ± SD of 5–9 animals. *P  < 0.05 versus  preincision and control times; †P  < 0.05 versus  vehicle; $ P  < 0.05 versus  0.94 nmol ARC.
×
Cholinergic Receptor Antagonist Effects of Clonidine and ST91 in Rats after Plantar Incision
Intrathecal injection of 94 nmol of clonidine increased the withdrawal threshold significantly 40 min after injection (fig. 4A). Intrathecal injection of atropine sulfate and mecamylamine significantly inhibited the antihypersensitivity effect of intrathecal clonidine (fig. 4A).
Fig. 4. Effect of intrathecal pretreatment with vehicle, atropine (a muscarinic cholinergic receptor antagonist), and mecamyla-mine (a nicotinic cholinergic receptor antagonist) on withdrawal thresholds before and after paw incision and after intrathecal injection of 94 nmol clonidine (A  , top  ) and of 59 nmol ST91 (B  , bottom  ). Each symbol represents the mean ± SD of 7–10 animals. *P  < 0.05 versus  preincision and control times; †P  < 0.05 versus  vehicle.
Fig. 4. Effect of intrathecal pretreatment with vehicle, atropine (a muscarinic cholinergic receptor antagonist), and mecamyla-mine (a nicotinic cholinergic receptor antagonist) on withdrawal thresholds before and after paw incision and after intrathecal injection of 94 nmol clonidine (A 
	, top 
	) and of 59 nmol ST91 (B 
	, bottom 
	). Each symbol represents the mean ± SD of 7–10 animals. *P 
	< 0.05 versus 
	preincision and control times; †P 
	< 0.05 versus 
	vehicle.
Fig. 4. Effect of intrathecal pretreatment with vehicle, atropine (a muscarinic cholinergic receptor antagonist), and mecamyla-mine (a nicotinic cholinergic receptor antagonist) on withdrawal thresholds before and after paw incision and after intrathecal injection of 94 nmol clonidine (A  , top  ) and of 59 nmol ST91 (B  , bottom  ). Each symbol represents the mean ± SD of 7–10 animals. *P  < 0.05 versus  preincision and control times; †P  < 0.05 versus  vehicle.
×
Intrathecal injection of 59 nmol ST91 increased the withdrawal threshold significantly 60 min after injection (fig. 4B). Neither intrathecal injection of atropine nor of mecamylamine altered the antihypersensitivity effect of intrathecal ST91 (fig. 4B). Intrathecal injection of vehicle or either antagonist alone failed to alter the withdrawal threshold (control time points:fig. 4).
Discussion
Anesthesiologists deal most commonly with acute pain associated with surgery. Despite the continuing evidence that most patients after surgery experience episodes of severe pain, 14 which can lead to development of chronic pain, 15 most pain research focuses on chronic inflammatory, metabolic, or neuropathic pain conditions. Seminal work by Brennan et al.  describing the behavioral, 11 neurophysiologic, 16 and pharmacologic 17 consequences and properties of surgery clearly indicate that postoperative pain differs in many fundamental ways from these other conditions, and we and others have argued that the relative lack of basic research in this area hampers better treatment for our postoperative patients. 18 The current study uses the method developed by Brennan et al.  11,16,17 and carries important implications for drug development and drug mechanisms.
Antinociceptive Potency of Intrathecal Clonidine Varies across Pain States
Like opioids, cyclooxygenase inhibitors, and glutamate receptor antagonists, the analgesic potency and maximum efficacy of intrathecal or epidural clonidine depends heavily on the type of clinical pain it is used to treat. This was first noted when the bolus or continuous infusion doses of epidural or intrathecal clonidine to effectively treat neuropathic pain 19 were found to be less than 25% those needed to treat postoperative 20–22 or obstetricpain. 23 Similarly, potency of clonidine to reduce experimentally induced allodynia was increased compared to treatment of acute noxious stimuli in normal volunteers, 24 indicating a shift in drug action or mechanism in the presence of central sensitization. These clinical observations are paralleled in studies with rodents, where generation of hypersensitivity from nerve injury increases potency and efficacy of intrathecal clonidine. 25,26 The current study in rats suggests that hypersensitivity to mechanical stimuli surrounding a skin incision lies closer in this regard to the normal condition than that following nerve injury. Intrathecal clonidine's potency in the current study of postoperative hypersensitivity is similar to that observed in rats to acute noxious stimuli. 27 
α2-Adrenoceptor Pharmacology of Intrathecal Clonidine Varies across Pain States
All three α2-adrenoceptor subtypes (A, B, and C) are present in rat spinal cord, 28 with a preponderance of α2A and α2C subtypes. 29 Anatomic and pharmacologic evidence suggests a shift in analgesic mechanisms of intrathecal clonidine from α2A predominant in the normal rat to α2C predominant after nerve injury. In the normal rat, antinociception of clonidine is reduced by acute knockdown of α2A adrenoceptors using antisense oligodeoxynucleotides 30 and reversed by the α2A adrenoceptor preferring antagonist, BRL44408. 8 Following nerve injury there is a loss of α2A adrenoceptor immunoreactivity in the spinal cord, but no change or an increase in α2C adrenoceptor immunoreactivity, 31 and antinociception of clonidine in this case is unresponsive to antagonism by BRL44408, but reversed by the α2non-A-adrenoceptor antagonist, ARC239. 8 
The current study suggests that the mix of α2-adrenoceptor subtypes responsible for clonidine antinociception following surgery is intermediate between that in the normal animal and that in the neuropathic animal. Thus, BRL44408 reversed clonidine's effect in the current study, indicating a role for α2A adrenoceptors, unlike the results after nerve injury. ARC239 was similarly potent to BRL44408 to reverse clonidine's effect in normal animals, 8 but was nearly 10-fold more potent to reverse clonidine's effect after surgery in the current study, indicating a partial, but not complete shift to an α2non-A-adrenoceptor mechanism.
Reliance of Intrathecal Clonidine on Spinal Cholinergic Systems Varies across Pain States
Stimulation of spinal cholinergic systems by intrathecal injection of α2-adrenoceptor agonists is widely documented in humans and animals. Thus, intrathecal clonidine increases acetylcholine concentrations in cerebrospinal fluid 32 and analgesic effect of clonidine is potentiated by intrathecal neostigmine in humans. 33 The reliance of antinociception from clonidine on this spinal cholinergic interaction varies between normal and nerve-injured animals. Thus, intrathecal clonidine antinociception to acute noxious thermal stimuli in normal rats is unaffected by intrathecal atropine or mecamylamine (unpublished observations, Xavier Paqueron, M.D., Research Fellow, Department of Anesthesiology, Wake Forest University School of Medicine, June 2000), but the reversal of hypersensitivity by clonidine following spinal nerve ligation is completely blocked by intrathecal atropine and partially blocked by intrathecal mecamyla-mine. 13 The current study suggests that postoperative hypersensitivity most resembles nerve injury–induced hypersensitivity in this regard since the effect of clonidine was completely antagonized by atropine and partially by mecamylamine. Should these data apply to humans, they provide a rationale for the study of epidural clonidine–neostigmine combinations for postoperative analgesia.
ST91 Antinociception Reflects Different Pharmacology from Clonidine
ST91, the diethyl derivative of clonidine, was described more than 25 yr ago to explain the lack of hypotensive and sedative properties of clonidine when administered systemically, originally ascribed to its hydrophilic nature. 34 Shortly thereafter, it was demonstrated to produce antinociception after intrathecal injection in rats, 35 but with a different structure activity relation for blockade by α2-adrenoceptor antagonists than clonidine or dexmedetomidine, 6,36 and with differential cross-tolerance with these agents, 37 suggesting it acted on different α2-adrenoceptor subtypes. More recent observations of synergistic interactions between dexmedetomidine and ST91 reinforce these early studies. 7 As in normal animals and those with spinal nerve ligation-induced hypersensitivity, 8 the effect of ST91 after surgery in the current study was reversed by the α2non-A-adrenoceptor antagonist ARC239 but was unaffected by the α2A-adrenoceptor–preferring antagonist BRL44408 or the cholinergic antagonists.
ST91 could represent an improvement on clonidine in the treatment of postoperative pain. Although ST91 exhibits less intrinsic activity than clonidine or dexmedetomidine in normal rats, 38 it is more effective than dexmedetomidine for antinociception in some strains of rats and in some thermal assays. 7 ST91 was more efficacious than clonidine in the current study, although whether this was due to a partial agonist effect of clonidine could not be determined, due to dose-limiting sedation by this agent. Sedation and hypotension limit the use of clonidine in the treatment of postoperative pain. 39 ST91 does not cause sedation after systemic or intrathecal administration, nor does it reduce blood pressure after intrathecal administration in several species. 5,34,35,40 Of course, human trials must await proper preclinical chemistry, formulation, stability, toxicity, and neurotoxicity studies.
In summary, intrathecal clonidine partially reverses the reduced withdrawal threshold to mechanical stimulation near a paw incision in rats through the actions of α2A- and α2non-A-adrenoceptor subtypes. This is also a mechanism that involves stimulation of spinal cholinergic receptors. These data suggest that the proportion of α2-adrenoceptor subtypes activated by clonidine to produce antinociception in the postoperative state differs from the normal animal with acute noxious stimuli and the nerve-injured animal with hypersensitivity. ST91 was more efficacious than clonidine, perhaps because larger relative doses could be administered without sedation, and it relied entirely on α2non-A-adrenoceptor subtypes. These data add to the growing literature indicating that postoperative pain exhibits a unique pharmacology of analgesia compared with acute experimental or chronic nerve injury pain. The data also provide the rationale for the clinical study of epidural clonidine–neostigmine combinations and for development of ST91 for clinical trials.
References
Bonnet F, Boico O, Rostaing S, Saada M, Loriferne JF, Touboul C, Abhay K, Ghignone M: Postoperative analgesia with extradural clonidine. Br J Anaesth 1989; 63: 465–9Bonnet, F Boico, O Rostaing, S Saada, M Loriferne, JF Touboul, C Abhay, K Ghignone, M
Chiari AI, Eisenach JC: Intrathecal adenosine: interactions with spinal clonidine and neostigmine in rat models of acute nociception and postoperative hypersensitivity. A nesthesiology 1999; 90: 1413–21Chiari, AI Eisenach, JC
Cheng JK, Pan HL, Eisenach JC: Antiallodynic effect of intrathecal gabapentin and its interaction with clonidine in a rat model of postoperative pain. A nesthesiology 2000; 92: 1126–31Cheng, JK Pan, HL Eisenach, JC
Saeki S, Yaksh TL: Suppression by spinal alpha-2 agonists of motor and autonomic responses evoked by low- and high-intensity thermal stimuli. J Pharmacol Exp Ther 1992; 260: 795–802Saeki, S Yaksh, TL
Eisenach JC, Tong C: Site of hemodynamic effects of intrathecal α2-adrenergic agonists. A nesthesiology 1991; 74: 766–71Eisenach, JC Tong, C
Takano Y, Yaksh TL: Characterization of the pharmacology of intrathecally administered Alpha  -2 agonists and antagonists in rats. J Pharmacol Exp Ther 1992; 261: 764–72Takano, Y Yaksh, TL
Graham BA, Hammond DL, Proudfit HK: Synergistic interactions between two α2-adrenoceptor agonists, dexmedetomidine and ST-91, in two substrains of Sprague-Dawley rats. Pain 2000; 85: 135–43Graham, BA Hammond, DL Proudfit, HK
Duflo F, Li X, Bantel C, Pancaro C, Vincler M, Eisenach JC: Peripheral nerve injury alters the α2-adrenoceptor subtype activated by clonidine for analgesia. A nesthesiology 2002; 97: 636–41Duflo, F Li, X Bantel, C Pancaro, C Vincler, M Eisenach, JC
Paqueron X, Li X, Bantel C, Tobin JR, Voytko ML, Eisenach JC: An obligatory role for spinal cholinergic neurons in the antiallodynic effects of clonidine after peripheral nerve injury. A nesthesiology 2001; 94: 1074–81Paqueron, X Li, X Bantel, C Tobin, JR Voytko, ML Eisenach, JC
Yaksh TL, Rudy TA: Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976; 7: 1032–6Yaksh, TL Rudy, TA
Brennan TJ, Vandermeulen EP, Gebhart GF: Characterization of a rat model of incisional pain. Pain 1996; 64: 493–501Brennan, TJ Vandermeulen, EP Gebhart, GF
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53: 55–63Chaplan, SR Bach, FW Pogrel, JW Chung, JM Yaksh, TL
Pan HL, Chen SR, Eisenach JC: Intrathecal clonidine alleviates allodynia in neuropathic rats: Interaction with spinal muscarinic and nicotinic receptors. A nesthesiology 1999; 90: 509–14Pan, HL Chen, SR Eisenach, JC
Lynch EP, Lazor MA, Gellis JE, Orav J, Goldman L, Marcantonio ER: Patient experience of pain after elective noncardiac surgery. Anesth Analg 1997; 85: 117–23Lynch, EP Lazor, MA Gellis, JE Orav, J Goldman, L Marcantonio, ER
Crombie IK, Davies HT, Macrae WA: Cut and thrust: Antecedent surgery and trauma among patients attending a chronic pain clinic. Pain 1998; 76: 167–71Crombie, IK Davies, HT Macrae, WA
Zahn PK, Brennan TJ: Incision-induced changes in receptive field properties of rat dorsal horn neurons. A nesthesiology 1999; 91: 772–85Zahn, PK Brennan, TJ
Brennan TJ, Umali EF, Zahn PK: Comparison of pre- versus post-incision administration of intrathecal bupivacaine and intrathecal morphine in a rat model of postoperative pain. A nesthesiology 1997; 87: 1517–28Brennan, TJ Umali, EF Zahn, PK
Eisenach JC: The treatment of pain: Remaining challenges and future opportunities. Can J Anaesth 2002; 49: R1–3Eisenach, JC
Eisenach JC, Rauck RL, Buzzanell C, Lysak SZ: Epidural clonidine analgesia for intractable cancer pain: Phase I. A nesthesiology 1989; 71: 647–52Eisenach, JC Rauck, RL Buzzanell, C Lysak, SZ
Mendez R, Eisenach JC, Kashtan K: Epidural clonidine analgesia after cesarean section. A nesthesiology 1990; 73: 848–52Mendez, R Eisenach, JC Kashtan, K
Filos KS, Goudas LC, Patroni O, Polyzou V: Intrathecal clonidine as a sole analgesic for pain relief after cesarean section. A nesthesiology 1992; 77: 267–74Filos, KS Goudas, LC Patroni, O Polyzou, V
Huntoon M, Eisenach JC, Boese P: Epidural clonidine after cesarean section: Appropriate dose and effect of prior local anesthetic. A nesthesiology 1992; 76: 187–93Huntoon, M Eisenach, JC Boese, P
Chiari A, Lorber C, Eisenach JC, Wildling E, Krenn C, Zavrsky A, Kainz C, Germann P, Klimscha W: Analgesic and hemodynamic effects of intrathecal clonidine as the sole analgesic agent during first stage of labor: A dose-response study. A nesthesiology 1999; 91: 388–96Chiari, A Lorber, C Eisenach, JC Wildling, E Krenn, C Zavrsky, A Kainz, C Germann, P Klimscha, W
Eisenach JC, Hood DD, Curry R: Relative potency of epidural to intrathecal clonidine differs between acute thermal pain and capsaicin-induced allodynia. Pain 2000; 84: 57–64Eisenach, JC Hood, DD Curry, R
Xu X-J, Puke MJC, Wiesenfeld-Hallin Z: The depressive effect of intrathecal clonidine on the spinal flexor reflex is enhanced after sciatic nerve section in rats. Pain 1992; 51: 145–51Xu, X-J Puke, MJC Wiesenfeld-Hallin, Z
Puke MJC, Wiesenfeld-Hallin Z: The differential effects of morphine and the α2-adrenoceptor agonists clonidine and dexmedetomidine on the prevention and treatment of experimental neuropathic pain. Anesth Analg 1993; 77: 104–9Puke, MJC Wiesenfeld-Hallin, Z
Howe JR, Wang JY, Yaksh TL: Selective antagonism of the antinociceptive effect of intrathecally applied alpha adrenergic agonists by intrathecal prazosin and intrathecal yohimbine. J Pharmacol Exp Ther 1983; 224: 552–8Howe, JR Wang, JY Yaksh, TL
Shi TJS, Winzer-Serhan U, Leslie F, Hökfelt T: Distribution of α2-adrenoceptor mRNAs in the rat lumbar spinal cord in normal and axotomized rats. Neuroreport 1999; 10: 2835–9Shi, TJS Winzer-Serhan, U Leslie, F Hökfelt, T
Stone LS, Broberger C, Vulchanova L, Wilcox GL, Hökfelt T, Riedl MS, Elde R: Differential distribution of α2Aand α2Cadrenergic receptor immunoreactivity in the rat spinal cord. J Neurosci 1998; 18: 5928–37Stone, LS Broberger, C Vulchanova, L Wilcox, GL Hökfelt, T Riedl, MS Elde, R
Hudson AL, Robinson ESJ, Lalies MD, Tyacke RJ, Jackson HC, Nutt DJ:In vitro  and in vivo  approaches to the characterization of the α2-adrenoceptor. J Auton Pharmacol 1999; 19: 311–20Hudson, AL Robinson, ESJ Lalies, MD Tyacke, RJ Jackson, HC Nutt, DJ
Stone LS, Vulchanova L, Riedl MS, Wang J, Williams FG, Wilcox GL, Elde R: Effects of peripheral nerve injury on alpha-2A and alpha-2C adrenergic receptor immunoreactivity in the rat spinal cord. Neuroscience 1999; 93: 1399–407Stone, LS Vulchanova, L Riedl, MS Wang, J Williams, FG Wilcox, GL Elde, R
De Kock M, Eisenach J, Tong C, Schmitz AL, Scholtes JL: Analgesic doses of intrathecal but not intravenous clonidine increase acetylcholine in cerebrospinal fluid in humans. Anesth Analg 1997; 84: 800–3De Kock, M Eisenach, J Tong, C Schmitz, AL Scholtes, JL
Hood DD, Mallak KA, Eisenach JC, Tong CY: Interaction between intrathecal neostigmine and epidural clonidine in human volunteers. A nesthesiology 1996; 85: 315–25Hood, DD Mallak, KA Eisenach, JC Tong, CY
Kobinger W, Pichler L: Investigation into some imidazoline compounds, with respect to peripheral α-adrenoceptor stimulation and depression of cardiovascular centers. Naunyn-Schmiedeberg's Archives of Pharmacology 1975; 291: 175–91Kobinger, W Pichler, L
Yasuoka S, Yaksh TL: Effects on nociceptive threshold and blood pressure of intrathecally administered morphine and α-adrenergic agonists. Neuropharmacol 1983; 22: 309–15Yasuoka, S Yaksh, TL
Takano Y, Takano M, Yaksh TL: The effect of intrathecally administered imiloxan and WB4101: Possible role of α2-adrenoceptor subtypes in the spinal cord. Eur J Pharmacol 1992; 219: 465–8Takano, Y Takano, M Yaksh, TL
Takano Y, Yaksh TL: Chronic spinal infusion of dexmedetomidine, ST-91 and clonidine: Spinal alpha  2adrenoceptor subtypes and intrinsic activity. J Pharmacol Exp Ther 1993; 264: 327–35Takano, Y Yaksh, TL
Takano Y, Yaksh TL: Relative efficacy of spinal alpha  -2 agonists, dexmedetomidine, clonidine and ST-91, determined in vivo  by using N-ethoxycarbonyl- 2-ethoxy-1,2-dihydroquinoline, an irreversible antagonist. J Pharmacol Exp Ther 1991; 258: 438–46Takano, Y Yaksh, TL
Eisenach JC, De Kock M, Klimscha W:α2-Adrenergic agonists for regional anesthesia: A clinical review of clonidine (1984–1995). A nesthesiology 1996; 85: 655–74Eisenach, JC De Kock, M Klimscha, W
Nagasaka H, Yaksh TL: Pharmacology of intrathecal adrenergic agonists: Cardiovascular and nociceptive reflexes in halothane-anesthetized rats. A nesthesiology 1990; 73: 1198–207 Intrathecal clonidine reduces hypersensitivity to a mechanical punctuate stimulus in rats following plantar incision of the paw by actions on both α2A and α2non-A adrenoceptors, and on interactions with spinal cholinergic receptors.Nagasaka, H Yaksh, TL
Fig. 1. Dose–response curves for the effects of intrathecally administered clonidine and ST91 on withdrawal threshold to mechanical stimulation near the paw incision site 24 h after surgery. The percent maximum possible effect (%MPE) is the percent return to presurgery withdrawal threshold. Each symbol represents the mean ± SD of 9 to 10 animals. *P  < 0.05 versus  clonidine.
Fig. 1. Dose–response curves for the effects of intrathecally administered clonidine and ST91 on withdrawal threshold to mechanical stimulation near the paw incision site 24 h after surgery. The percent maximum possible effect (%MPE) is the percent return to presurgery withdrawal threshold. Each symbol represents the mean ± SD of 9 to 10 animals. *P 
	< 0.05 versus 
	clonidine.
Fig. 1. Dose–response curves for the effects of intrathecally administered clonidine and ST91 on withdrawal threshold to mechanical stimulation near the paw incision site 24 h after surgery. The percent maximum possible effect (%MPE) is the percent return to presurgery withdrawal threshold. Each symbol represents the mean ± SD of 9 to 10 animals. *P  < 0.05 versus  clonidine.
×
Fig. 2. Effect of intrathecal pretreatment with vehicle BRL44408 (α2A-subtype–preferring antagonist) (A  , top  ) and ARC239 (α2non-A subtype preferring antagonist) (B  , bottom  ) on withdrawal thresholds before and after paw incision and after intrathecal injection of 94 nmol clonidine. Each symbol represents the mean ± SD of 8–10 animals. *P  < 0.05 versus  preincision and control times; †P  < 0.05 versus  vehicle; $ P  < 0.05 versus  9.4 nmol dose of BRL.
Fig. 2. Effect of intrathecal pretreatment with vehicle BRL44408 (α2A-subtype–preferring antagonist) (A 
	, top 
	) and ARC239 (α2non-A subtype preferring antagonist) (B 
	, bottom 
	) on withdrawal thresholds before and after paw incision and after intrathecal injection of 94 nmol clonidine. Each symbol represents the mean ± SD of 8–10 animals. *P 
	< 0.05 versus 
	preincision and control times; †P 
	< 0.05 versus 
	vehicle; $ P 
	< 0.05 versus 
	9.4 nmol dose of BRL.
Fig. 2. Effect of intrathecal pretreatment with vehicle BRL44408 (α2A-subtype–preferring antagonist) (A  , top  ) and ARC239 (α2non-A subtype preferring antagonist) (B  , bottom  ) on withdrawal thresholds before and after paw incision and after intrathecal injection of 94 nmol clonidine. Each symbol represents the mean ± SD of 8–10 animals. *P  < 0.05 versus  preincision and control times; †P  < 0.05 versus  vehicle; $ P  < 0.05 versus  9.4 nmol dose of BRL.
×
Fig. 3. Effect of intrathecal pretreatment with vehicle ARC239 (α2non-A-subtype–preferring antagonist) (A  , top  ) and BRL44408 (α2A-subtype–preferring antagonist) (B  , bottom  ) on withdrawal thresholds before and after paw incision and after intrathecal injection of 59 nmol ST91. Each symbol represents the mean ± SD of 5–9 animals. *P  < 0.05 versus  preincision and control times; †P  < 0.05 versus  vehicle; $ P  < 0.05 versus  0.94 nmol ARC.
Fig. 3. Effect of intrathecal pretreatment with vehicle ARC239 (α2non-A-subtype–preferring antagonist) (A 
	, top 
	) and BRL44408 (α2A-subtype–preferring antagonist) (B 
	, bottom 
	) on withdrawal thresholds before and after paw incision and after intrathecal injection of 59 nmol ST91. Each symbol represents the mean ± SD of 5–9 animals. *P 
	< 0.05 versus 
	preincision and control times; †P 
	< 0.05 versus 
	vehicle; $ P 
	< 0.05 versus 
	0.94 nmol ARC.
Fig. 3. Effect of intrathecal pretreatment with vehicle ARC239 (α2non-A-subtype–preferring antagonist) (A  , top  ) and BRL44408 (α2A-subtype–preferring antagonist) (B  , bottom  ) on withdrawal thresholds before and after paw incision and after intrathecal injection of 59 nmol ST91. Each symbol represents the mean ± SD of 5–9 animals. *P  < 0.05 versus  preincision and control times; †P  < 0.05 versus  vehicle; $ P  < 0.05 versus  0.94 nmol ARC.
×
Fig. 4. Effect of intrathecal pretreatment with vehicle, atropine (a muscarinic cholinergic receptor antagonist), and mecamyla-mine (a nicotinic cholinergic receptor antagonist) on withdrawal thresholds before and after paw incision and after intrathecal injection of 94 nmol clonidine (A  , top  ) and of 59 nmol ST91 (B  , bottom  ). Each symbol represents the mean ± SD of 7–10 animals. *P  < 0.05 versus  preincision and control times; †P  < 0.05 versus  vehicle.
Fig. 4. Effect of intrathecal pretreatment with vehicle, atropine (a muscarinic cholinergic receptor antagonist), and mecamyla-mine (a nicotinic cholinergic receptor antagonist) on withdrawal thresholds before and after paw incision and after intrathecal injection of 94 nmol clonidine (A 
	, top 
	) and of 59 nmol ST91 (B 
	, bottom 
	). Each symbol represents the mean ± SD of 7–10 animals. *P 
	< 0.05 versus 
	preincision and control times; †P 
	< 0.05 versus 
	vehicle.
Fig. 4. Effect of intrathecal pretreatment with vehicle, atropine (a muscarinic cholinergic receptor antagonist), and mecamyla-mine (a nicotinic cholinergic receptor antagonist) on withdrawal thresholds before and after paw incision and after intrathecal injection of 94 nmol clonidine (A  , top  ) and of 59 nmol ST91 (B  , bottom  ). Each symbol represents the mean ± SD of 7–10 animals. *P  < 0.05 versus  preincision and control times; †P  < 0.05 versus  vehicle.
×